AstraZeneca PLC (AZN) | Statement of Cash Flows
The cash flow statement provides information about a company's cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company's statement of financial position.
The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.
AstraZeneca PLC, Consolidated Statement of Cash Flows
USD $ in millions
| 12 months ended | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
|---|---|---|---|---|---|---|
| Profit before tax | 7,718 | 12,367 | 10,977 | 10,807 | 8,681 | |
| Finance income and expense | 430 | 428 | 517 | 736 | 463 | |
| Depreciation, amortization and impairment | 2,518 | 2,550 | 2,741 | 2,087 | 2,620 | |
| (Increase) decrease in trade and other receivables | 755 | (1,108) | 10 | (256) | (1,032) | |
| (Increase) decrease in inventories | (150) | (256) | 88 | 6 | 185 | |
| Increase (decrease) in trade and other payables and provisions | (1,311) | 467 | (16) | 1,579 | 637 | |
| Profit on disposal of subsidiary | – | (1,483) | – | – | – | |
| Non-cash and other movements | (424) | (597) | (463) | (200) | 87 | |
| Cash generated from operations | 9,536 | 12,368 | 13,854 | 14,759 | 11,641 | |
| Interest paid | (545) | (548) | (641) | (639) | (690) | |
| Tax paid | (2,043) | (3,999) | (2,533) | (2,381) | (2,209) | |
| Dividends received | 7 | – | – | – | – | |
| Interest received | 145 | 171 | 174 | 113 | 149 | |
| Net cash inflow from operating activities | 7,100 | 7,992 | 10,854 | 11,852 | 8,891 | |
| Acquisitions of business operations | (1,187) | – | (348) | – | – | |
| Movement in short term investments and fixed deposits | 3,619 | (2,743) | (125) | (1,339) | 1 | |
| Purchase of property, plant and equipment | (672) | (839) | (791) | (962) | (1,095) | |
| Disposal of property, plant and equipment | 199 | 102 | 83 | 138 | 38 | |
| Purchase of intangible assets | (3,947) | (458) | (1,390) | (624) | (2,944) | |
| Disposal of intangible assets | – | – | 210 | 269 | – | |
| Purchase of non-current asset investments | (46) | (11) | (34) | (31) | (40) | |
| Disposal of non-current asset investments | 43 | – | 5 | 3 | 32 | |
| Net cash received on disposal of subsidiary | – | 1,772 | – | – | – | |
| Payments made by subsidiaries to non-controlling interests | (20) | (16) | (10) | (11) | (37) | |
| Net cash outflow from investing activities | (2,011) | (2,193) | (2,400) | (2,557) | (4,045) | |
| Proceeds from issue of share capital | 429 | 409 | 494 | 135 | 159 | |
| Repurchase of shares | (2,635) | (6,015) | (2,604) | – | (610) | |
| Repayment of obligations under finance leases | (17) | – | – | – | – | |
| Issue of loans | 1,980 | – | – | – | 787 | |
| Repayment of loans | (1,750) | – | (1,741) | (650) | – | |
| Dividends paid | (3,665) | (3,764) | (3,361) | (2,977) | (2,739) | |
| Hedge contracts relating to dividend payments | 48 | 3 | (114) | (32) | – | |
| Movement in short term borrowings | 687 | 46 | (8) | (137) | (3,959) | |
| Net cash outflow from financing activities | (4,923) | (9,321) | (7,334) | (3,661) | (6,362) | |
| Exchange rate effects | (4) | (25) | 33 | 71 | (88) | |
| Net increase (decrease) in cash and cash equivalents in the period | 162 | (3,547) | 1,153 | 5,705 | (1,604) | |
| Cash and cash equivalents at beginning of the period | 7,434 | 10,981 | 9,828 | 4,123 | 5,727 | |
| Cash and cash equivalents at the end of the period | 7,596 | 7,434 | 10,981 | 9,828 | 4,123 |
| Item | Description | The company |
|---|---|---|
| Net cash inflow from operating activities | The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. | AstraZeneca PLC's net cash inflow from operating activities declined from 2010 to 2011 and from 2011 to 2012. |
ADVERTISEMENT